Afficher la notice abrégée

dc.rights.licenseopenen_US
dc.contributor.authorTOUILLAUD, M.
dc.contributor.authorGELOT, A.
dc.contributor.authorMESRINE, S.
dc.contributor.authorBENNETAU, Catherine
dc.contributor.authorCLAVEL-CHAPELON, F.
dc.contributor.authorARVEUX, P.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorBONNET, Fabrice
dc.contributor.authorGUNTER, M.
dc.contributor.authorBOUTRON-RUAULT, M. C.
dc.contributor.authorFOURNIER, A.
dc.date.accessioned2020-07-15T09:08:15Z
dc.date.available2020-07-15T09:08:15Z
dc.date.issued2019-03-01
dc.identifier.issn0002-9165en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/10476
dc.description.abstractEnBACKGROUND: Soy-based dietary supplements have been promoted as natural alternatives to menopausal hormone therapy, but their potential effect on breast cancer development is controversial. OBJECTIVES: We examined the relation between the consumption of soy supplements and the risk of breast cancer, overall and by tumor hormone receptor status, among women aged >50 y. METHODS: In total, 76,442 women from the Etude Epidemiologique aupres de Femmes de la Mutuelle Generale de l'Education Nationale (E3N) cohort, born between 1925 and 1950, were followed from 2000 to 2011 (11.2 y on average, starting at a mean age of 59.5 y; 3608 incident breast cancers), with soy supplement use assessed every 2-3 y. HRs of breast cancer were estimated with the use of multivariable Cox models. RESULTS: Compared with never using soy supplements, the HRs associated with current use of soy supplements were 0.92 (95% CI: 0.76, 1.11) for all, 0.78 (95% CI: 0.60, 0.99) for estrogen receptor (ER)-positive, and 2.01 (95% CI: 1.41, 2.86) for ER-negative breast cancers. There was no association between past use of soy supplements and breast cancer. HRs for current use were 1.36 (95% CI: 0.95, 1.93) and 0.82 (95% CI: 0.65, 1.02) among women with and without a family history of breast cancer, respectively (P-interaction = 0.03) and 1.06 (95% CI: 0.87, 1.30) >/=5 y after menopause compared with 0.50 (95% CI: 0.31, 0.81) in premenopause or </=5 y postmenopause (P-interaction = 0.04). CONCLUSIONS: In this cohort of women aged >50 y, we report opposing associations of soy supplements with ER-positive and ER-negative breast cancer risk. Our results also caution against the use of these supplements in women with a family history of breast cancer. Whether the risk profile of soy supplements could be more favorable among premenopausal or recently postmenopausal women deserves further investigation.
dc.language.isoENen_US
dc.subject.enMORPH3Eus
dc.title.enUse of dietary supplements containing soy isoflavones and breast cancer risk among women aged >50 y: a prospective study
dc.typeArticle de revueen_US
dc.identifier.doi10.1093/ajcn/nqy313en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed30831601en_US
bordeaux.journalAmerican Journal of Clinical Nutritionen_US
bordeaux.page597-605en_US
bordeaux.volume109en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - U1219en_US
bordeaux.issue3en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03212254
hal.version1
hal.date.transferred2021-04-29T12:28:24Z
hal.exporttrue
bordeaux.COinSctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft.jtitle=American%20Journal%20of%20Clinical%20Nutrition&amp;rft.date=2019-03-01&amp;rft.volume=109&amp;rft.issue=3&amp;rft.spage=597-605&amp;rft.epage=597-605&amp;rft.eissn=0002-9165&amp;rft.issn=0002-9165&amp;rft.au=TOUILLAUD,%20M.&amp;GELOT,%20A.&amp;MESRINE,%20S.&amp;BENNETAU,%20Catherine&amp;CLAVEL-CHAPELON,%20F.&amp;rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée